<div id="readability-page-1"><p>SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading activity on Friday. Traders acquired 21,865 call options on the company. This is an increase of approximately 95% compared to the average volume of 11,198 call options.</p><h2>Insider Activity</h2><p>In other news, Director Katherine Bach Kalin acquired 63,400 shares of the business's stock in a transaction on Wednesday, November 19th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the acquisition, the director directly owned 104,400 shares of the company's stock, valued at $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 1.40% of the stock is owned by insiders. </p><h2>Hedge Funds Weigh In On SELLAS Life Sciences Group</h2><p>A number of hedge funds have recently made changes to their positions in SLS. Axxcess Wealth Management LLC purchased a new position in shares of  SELLAS Life Sciences Group during the third quarter worth approximately $26,000.  BNP Paribas Financial Markets increased its stake in shares of  SELLAS Life Sciences Group by 89.2% during the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after buying an additional 9,299 shares during the period.  Blair William &amp; Co. IL purchased a new stake in  SELLAS Life Sciences Group in the 2nd quarter valued at $35,000.  ProShare Advisors LLC acquired a new position in  SELLAS Life Sciences Group in the 2nd quarter valued at about $43,000.  Finally, Sei Investments Co. purchased a new position in  SELLAS Life Sciences Group in the 3rd quarter valued at $43,000. Institutional investors own  17.38% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>Separately, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One analyst  has rated the stock with a Buy rating and one  has issued  a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and an average price target of $7.00.</p><p><b>Read Our Latest Research Report on SLS</b></p><h2>SELLAS Life Sciences Group Stock Performance</h2><p>Shares of NASDAQ:SLS traded up $0.06 during midday trading on Friday, hitting $2.40. 2,337,140 shares of the stock were exchanged, compared to its average volume of 2,993,071. The stock has a market capitalization of $341.15 million, a price-to-earnings ratio of -8.55 and a beta of 2.51. SELLAS Life Sciences Group has a 12 month low of $0.85 and a 12 month high of $2.48. The business's 50-day moving average price is $1.78 and its 200 day moving average price is $1.77. </p><p>SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02.  As a group, sell-side analysts expect that  SELLAS Life Sciences Group will post -0.57 EPS for the current year. </p><h2>About SELLAS Life Sciences Group</h2> (Get Free Report)<p>SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.  </p><p>The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.</p><h2>See Also</h2><ul><li>Five stocks we like better than SELLAS Life Sciences Group</li><li>Following Congress Stock Trades</li><li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>TL;DR: Why Reddit is the New Growth Stock to Beat</li><li>What Are Dividend Challengers?</li><li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?</h2><p>Before you consider SELLAS Life Sciences Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.</p><p>While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>SELLAS Life Sciences Group (NASDAQ:SLS) experienced a significant increase in options trading activity, with 21,865 call options acquired, a 95% rise from the average. The stock traded at $2.40, up $0.06, with a market cap of $341.15 million. Insider and hedge fund activities were noted, and analysts have mixed ratings on the stock. The company focuses on cancer immunotherapies.</p>

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)